Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India
Shots:
- The company received DCGI’s MA for Teriparatide (biosimilar) for the treatment of Osteoporosis vs anti-resorptive therapies such as bisphosphates and SERMs
- The approved product will be marketed through Alkem Laboratories as well as it explore other potential partnering opportunities
- Teriparatide will be launched in a fully compliant pen device
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
